The four pillars of our Commitment

Respecting and understanding the patient community perspective

Expanding access to our medicines

Conducting responsible clinical trials

We recognize the importance of patients and caregivers understanding what they can expect from Novartis.
in general medicines obtained patient insights before first-in-human trials (healthy volunteers). Piloted patient panels for five Proof of Concept indications.
95% requests approved for 62 compounds in 95 countries - providing pre-approval access to Novartis medicines. At the end of 2021, more than 13 000 patients were receiving treatment through MAPs.
comprising 70 clinical trials, had a patient engagement component to obtain the patient perspective on the design and/or conduct of clinical trials.
included Patient Reported Outcomes (PRO) conducted in 72 countries.
from Phase 1-4 clinical trials sent to investigators to share with 27 013 trial participants and posted on novartis.com/clinicaltrials.
reached through access approaches.
Clinical trials are scientific studies conducted to find better ways to prevent, screen for, diagnose or treat disease.
Novartis is currently conducting clinical trials around the world for a number of diseases.
Novartis Managed Access makes investigational or unapproved treatments available to eligible patients with serious or life-threatening diseases. Your physician may request access.
Diversity in clinical trials is integral to who we are at Novartis and we are working hard to improve both the diversity of patients enrolled in our clinical research and the investigators involved in our trials. (PDF 0.2 MB)
Global Oncology Patient Insights Panels (GOPIPs) are giving patients and advocates a critical voice in advancing lung cancer trials.
For questions about Novartis, medical inquiries about our products and/or information about services, we recommend you contact the Novartis office in your country. If you’re seeking a global list of products, visit our Global Product Portfolio.